GlassScriptPhysician profile
Kandice M Walker
NPI 1063811834
$12,907.83
in general payments reported to CMS, 2019-2025
67 companies · $3,937 in 2025
The $3,937 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $391 · 2022: $1,755 · 2023: $3,396 · 2024: $3,429 · 2025: $3,937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $660 · Education: $44.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,057.51 |
| Consulting Fee | $660.00 |
| Education | $44.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $975.50 | 2022-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $866.60 | 2021-2025 | Enhertu, Imfinzi, Lynparza |
| Gilead Sciences, INC. | $772.74 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $747.44 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $729.44 | 2022-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $664.21 | 2022-2025 | Opdivo, Opdualag, Augtyro |
| Stemline Therapeutics INC. | $660.00 | 2025 | Orserdu |
| Celgene Corporation | $635.41 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Eisai INC. | $557.97 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $491.41 | 2022-2025 | |
| Janssen Biotech, INC. | $445.65 | 2021-2025 | Talvey, Darzalex, Erleada |
| Pfizer INC. | $421.39 | 2022-2025 | |
| Genzyme Corporation | $399.73 | 2021-2025 | |
| Glaxosmithkline, LLC. | $330.39 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Beigene USA, INC. | $304.48 | 2021-2024 | Brukinsa |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $278.47 | 2022-2023 | Cosela |
| Lilly USA, LLC | $257.81 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $257.55 | 2022-2025 | Phesgo, Perjeta, Venclexta |
| Seagen INC. | $253.71 | 2022-2023 | Tukysa |
| Incyte Corporation | $203.96 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $183.29 | 2022-2025 | Ninlaro, Iclusig, Vpriv |
| Puma Biotechnology, INC. | $137.65 | 2023-2025 | |
| Abbvie INC. | $128.35 | 2021-2025 | |
| Taiho Oncology, INC. | $122.39 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.77 | 2021-2025 | |
| Amgen INC. | $109.94 | 2021-2023 | Nplate, Vectibix, Xgeva |
| Emd Serono, INC. | $100.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $96.56 | 2023 | Libtayo |
| Springworks Therapeutics, INC. | $93.40 | 2025 | Ogsiveo |
| Tersera Therapeutics LLC | $87.76 | 2023-2024 | Zoladex |
| Geron Corporation | $81.19 | 2025 | Rytelo |
| Rigel Pharmaceuticals, INC. | $73.91 | 2021-2023 | Rezlidhia, Tavalisse |
| Kyowa Kirin, INC. | $73.20 | 2021-2024 | Poteligeo |
| Agios Pharmaceuticals, INC. | $72.50 | 2023-2024 | Pyrukynd |
| Servier Pharmaceuticals LLC | $71.94 | 2023-2025 | |
| Deciphera Pharmaceuticals INC. | $68.25 | 2022-2023 | Qinlock |
| Astellas Pharma US INC | $66.98 | 2023-2025 | Xospata, Vyloy |
| Genmab U.S., INC. | $66.88 | 2023-2025 | Epkinly |
| Alexion Pharmaceuticals, INC. | $62.90 | 2022-2024 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.64 | 2025 | |
| Array Biopharma INC | $55.95 | 2025 | Braftovi, Lorbrena, Mektovi |
| Beone Medicines USA, INC. | $49.32 | 2025 | Brukinsa, Tevimbra |
| Blueprint Medicines Corporation | $45.52 | 2022-2024 | Ayvakit |
| Aveo Pharmaceuticals, INC. | $43.31 | 2022-2025 | |
| Sobi, INC | $42.10 | 2024 | |
| Legend Biotech USA INC. | $41.41 | 2025 | Carvykti |
| Janssen Pharmaceuticals, INC | $41.14 | 2022-2024 | Xarelto |
| Jazz Pharmaceuticals INC. | $40.19 | 2024-2025 | |
| Coherus Oncology, INC. | $35.55 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $34.06 | 2022-2025 | Xpovio |
| Morphosys, US INC. | $33.62 | 2022-2023 | Monjuvi |
| Pharmaessentia USA Corporation | $33.17 | 2024-2025 | Besremi |
| Adc Therapeutics America, INC. | $31.09 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $29.14 | 2023 | Orgovyx |
| Azurity Pharmaceuticals, INC. | $25.00 | 2025 | Danziten |
| Adaptive Biotechnologies Corporation | $21.18 | 2024 | Clonoseq |
| Ipsen Biopharmaceuticals, INC | $20.10 | 2021 | |
| Sun Pharmaceutical Industries INC. | $18.03 | 2024 | |
| Pharmacosmos Therapeutics INC. | $17.11 | 2024 | Cosela |
| Amag Pharmaceuticals, INC. | $16.83 | 2021 | |
| Syndax Pharmaceuticals, INC. | $16.75 | 2025 | |
| Apellis Pharmaceuticals, INC. | $16.25 | 2023 | Empaveli |
| Celltrion USA INC. | $16.21 | 2025 | Vegzelma |
| Pharmacyclics LLC, An Abbvie Company | $16.01 | 2023 | Imbruvica |
| Dova Pharmaceuticals | $14.92 | 2021 | |
| Secura Bio, INC. | $14.76 | 2022 | |
| Iovance Biotherapeutics, INC. | $11.75 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kandice Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.